Literature DB >> 25574983

A comparative study on use of 3% saline versus 0.9% saline nebulization in children with bronchiolitis.

A R Ojha1, S Mathema1, S Sah1, U R Aryal2.   

Abstract

BACKGROUND: Bronchiolitis is a common clinical problem in children below 2 years presenting with respiratory symptoms. As there is necrosis and sloughing of epithelial cells, edema, increased secretion of mucus causing obstruction of large and small airways we aim to see the clinical profile and the effect of use of hypertonic (3%) saline nebulization in these children.
METHODS: A double blind randomized controlled trial was conducted at department of Pediatrics, in a hospital from July 2012 to August 2013. The computer generated random number was used to select the case and control group. All eligible patients were randomly assigned to one of two groups: receiving inhalation of 4 ml normal (0.9%) saline or hypertonic (3%) saline. Treating physicians, researchers and nurses were all blinded of the solution. Both saline were kept in two identical containers and labeled as solution A and solution B. Patients in each group will receive three treatments on each day of hospitalization and clinical score were obtained 30 minutes before each inhalation session.
RESULTS: Bronchiolitis accounted 11.26% of total admissions. Their mean age (±SD) was 8.56 (±5.013) months with range from 45 days to 24 months. A total of 53 (74%) male were enrolled in the study. Fifty-seven (79%) children were less than 12 months and 15 (21%) were 12 months - 24 months. The mean (±SD) for duration of hospital stay was 44.82 (±23.15) and 43.60 (±28.25) for 3% and 0.9% group respectively (p=0.86). Likewise, mean (SD) duration of oxygen supplementation was 32.50 (±20.44) and 34.50 (±26.03) for 3% and 0.9% group respectively (p=0.85). Moreover, time required for normalization of clinical score was 36.79 (±19.53) and 38.34 (±26.67) for 3% and 0.9% group respectively (p=0.80).
CONCLUSIONS: There is no advantage of hypertonic saline over normal saline nebulization in the management bronchiolitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25574983

Source DB:  PubMed          Journal:  J Nepal Health Res Counc        ISSN: 1727-5482


  6 in total

Review 1.  Nebulised hypertonic saline solution for acute bronchiolitis in infants.

Authors:  Linjie Zhang; Raúl A Mendoza-Sassi; Claire Wainwright; Terry P Klassen
Journal:  Cochrane Database Syst Rev       Date:  2017-12-21

Review 2.  Hypertonic Saline for the Treatment of Bronchiolitis in Infants and Young Children: A Critical Review of the Literature.

Authors:  Jeffrey Baron; Gladys El-Chaar
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

Review 3.  The cost-effectiveness of hypertonic saline inhalations for infant bronchiolitis: a decision analysis.

Authors:  Paula Heikkilä; Minna Mecklin; Matti Korppi
Journal:  World J Pediatr       Date:  2018-02-23       Impact factor: 2.764

Review 4.  Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis.

Authors:  Chin Maguire; Hannah Cantrill; Daniel Hind; Mike Bradburn; Mark L Everard
Journal:  BMC Pulm Med       Date:  2015-11-23       Impact factor: 3.317

5.  Network Meta-Analysis Comparing the Efficacy of Therapeutic Treatments for Bronchiolitis in Children.

Authors:  Caili Guo; Xiaomin Sun; Xiaowen Wang; Qing Guo; Dan Chen
Journal:  JPEN J Parenter Enteral Nutr       Date:  2017-11-03       Impact factor: 4.016

6.  Exploring the efficacy of using hypertonic saline for nebulizing treatment in children with bronchiolitis: a meta-analysis of randomized controlled trials.

Authors:  Chia-Wen Hsieh; Chiehfeng Chen; Hui-Chuan Su; Kee-Hsin Chen
Journal:  BMC Pediatr       Date:  2020-09-14       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.